Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PMDA to Upgrade Reviewers' Scientific Expertise
December 6, 2010
- Astellas to Increase Market Share for Vesicare with OD Tablets
December 6, 2010
- No. of Generics Listed in November Announced by Korosho
December 6, 2010
- Inavir Can Complete Treatment with a Single Dose: Daiichi Sankyo
December 6, 2010
- PMDA's Project Team Proposes East Asian Central Review System
December 6, 2010
- Novartis to Globally Apply for 13 Drugs in 2011, 9 in 2012
December 6, 2010
- Approval of Two Implantable Heart Assist Systems Recommended
December 6, 2010
- Toho Expects One Point Reduction in Yakkasa on Full-Year Basis
December 6, 2010
- Ono Aims at Sales of ¥10 Bil. for Emend
December 6, 2010
- Need for Closer Cooperation Reconfirmed at 4th THMM
December 6, 2010
- Major Dispensing Pharmacy Chains Introduce More Automatic Dispensing Systems
December 6, 2010
- EPS: Sales Up 25% Driven by CSO Business
December 6, 2010
- Efficacy Not Confirmed for NV1FGF in PIII: AHA
December 6, 2010
- Use of Points for Out-of-Pocket Payments Unacceptable: JPA
December 6, 2010
- Safety, Efficacy of Anacetrapib Confirmed in PIII: AHA
December 6, 2010
- Novartis, sanofi-aventis to Copromote Equa
December 6, 2010
- BMS, Pfizer Discontinue Apixaban Development for ACS
December 6, 2010
- JPMA to Organize “Asian Liaison Conference”
November 29, 2010
- End of R&D Tax Break to Result in Tax Increases for Pharma Industry: PMDA
November 29, 2010
- BioWa Licenses POTELLIGENT Technology to Agensys
November 29, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…